fentanyl transmucosal and pentobarbital both raise sedation. Prevent or Use Alternate Drug. Restrict use to sufferers for whom substitute treatment method selections are insufficient
If a CYP3A4 inducer is discontinued inside a patient who has been stabilized on buprenorphine, keep track of the patient for overmedication.Really serious - Use Choice (1)buprenorphine subdermal implant and pentobarbital both maximize sedation. Prevent or Use Alternate Drug. Limit use to sufferers for whom option procedure possibilities are inadequate
pentobarbital will reduce the level or effect of alosetron by impacting hepatic enzyme CYP2C9/ten metabolism. Insignificant/Significance Unidentified.
pentobarbital will lessen the extent or influence of oliceridine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch. If coadministration that has a CYP3A4 inducer is necessary, look at escalating oliceridine dose right until secure drug outcomes are reached; watch for signs of opioid withdrawal.
pentobarbital will decrease the extent or effect of ramelteon by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Unknown.
With therapeutic doses of TCAs, barbiturates maximize metabolism and reduce blood concentrations of TCAs.
Keep an eye on Carefully (one)pentobarbital will lessen the extent or influence of cannabidiol by influencing hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will reduce the extent or influence of lonafarnib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lonafarnib is actually a delicate CYP3A4 substrate. Coadministration with solid or reasonable CYP3A4 inducers is contraindicated.
pentobarbital will decrease the extent or result of ixabepilone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.
pentobarbital improves toxicity of ifosfamide by impacting hepatic/intestinal enzyme CYP3A4 metabolism. 戊巴比妥鈉製作 Use Caution/Monitor. CYP3A4 inducers may perhaps improve the metabolism of ifosfamide to its active alkylating metabolites.
pentobarbital will lessen the level or result of darunavir by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.
Reserve concomitant prescribing of those prescription drugs in sufferers for whom other therapy selections are inadequate. Limit dosages and durations to the minimum amount demanded. Keep an eye on carefully for indications of respiratory despair and sedation.
pentobarbital will decrease the extent or impact of guanfacine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Check Intently. Strong or moderate CYP3A4 inducers drastically decrease guanfacine plasma concentrations and elimination fifty percent-lifestyle.
Induction of microsomal enzymes by this drug, may shorten the 50 percent-lifetime of doxycycline for as long as two months after barbiturate therapy discontinued; keep track of clinical response to doxycycline intently if both drugs administered concurrently